1-3 of 3
histiocytosis, langerhans-cell
Close
Sort by
Journal Articles

Circulating CD1c + myeloid dendritic cells are potential precursors to LCH lesion CD1a + CD207 + cells

Karen Phaik Har Lim, Paul Milne, Michael Poidinger, Kaibo Duan, Howard Lin, Naomi McGovern, Harshal Abhyankar, Daniel Zinn, Thomas M. Burke, Olive S. Eckstein, Rikhia Chakraborty, Amel Sengal, Brooks Scull, Evan Newell, Miriam Merad, Kenneth L. McClain, Tsz-Kwong Man, Florent Ginhoux, Matthew Collin, Carl E. Allen
Journal: Blood Advances
Blood Adv (2020) 4 (1): 87–99.
https://doi.org/10.1182/bloodadvances.2019000488
Published: 2020
Includes: Supplemental data
Journal Articles

BRAF -V600E–mutated Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis with response to BRAF inhibitor

Clinical Trials & Observations
Rosemarie Mastropolo, Allison Close, Steven W. Allen, Kenneth L. McClain, Scott Maurer, Jennifer Picarsic
Journal: Blood Advances
Blood Adv (2019) 3 (12): 1848–1853.
https://doi.org/10.1182/bloodadvances.2019000093
Published: 2019
Includes: Supplemental data
Journal Articles

Long-term disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition

Clinical Trials & Observations
Gil Awada, Teofila Seremet, Karel Fostier, Hendrik Everaert, Bart Neyns
Journal: Blood Advances
Blood Adv (2018) 2 (16): 2156–2158.
https://doi.org/10.1182/bloodadvances.2018021782
Published: 2018